By Steve Edelson
Staff writer

Amgen Inc.'s decision to spend $100 million this year to develop Praecis Pharmaceuticals Inc.'s abarelix to treat prostate cancer represents the second big partnership commitment for the gonadotropin releasing hormone antagonist. Last week's AMGN deal for the U.S., Canada, Australia and Asia on top of Synthelabo SA's buy-in in 1997, stems from abarelix's improved side effect profile compared to other GnRH antagonists as well as approved hormonal superagonists and anti-androgens.